AI study led by Insilico's Alex Zhavoronkov bolsters case for faster, cheaper drug discovery

Natalie Grover

Reporter

Drug development is an arduous and expensive business. The promise of artificial intelligence is that machines can wean manufacturers away from the breadth of resources …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AI study led by Insilico's Alex Zhavoronkov bolsters case for faster, cheaper drug discovery

Natalie Grover

Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Novartis highlights overall M&A track record following MorphoSys impairment

Following March inspection, Novo Nordisk's semaglutide manufacturing facility cited by FDA

AI study led by In­sil­i­co's Alex Zha­voronkov bol­sters case for faster, cheap­er drug dis­cov­ery

Reporter

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

AI study led by Insilico's Alex Zhavoronkov bolsters case for faster, cheaper drug discovery